Mr. Adrian Mendes reports

PERIMETER MEDICAL IMAGING AI ANNOUNCES INITIATION OF NEW CLINICAL TRIAL SITE AT UNIVERSITY OF WASHINGTON/FRED HUTCH CANCER CENTER

Perimeter Medical Imaging AI Inc. has initiated an additional clinical trial site at the University of Washington/Fred Hutch Cancer Center, located in Seattle, Wash.

Perimeter is conducting a continuing multicentre, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software when used during breast conservation surgeries.

Dr. Meghan R. Flanagan, MD, MPD, University of Washington/Fred Hutch Cancer Center, stated: "Recognizing the unmet need in the field of breast cancer margin visualization, we are pleased to become the most recent site to participate in this clinical study. Combining AI [artificial intelligence] with high-resolution imaging has the potential to become a new standard of care during breast conservation surgery, by reducing the number of repeat surgeries and, ultimately, delivering better outcomes for patients."

Adrian Mendes, Perimeter's chief executive officer, stated: "We are focused on expediting the development of our next-gen AI technology and its clinical evaluation in an ongoing pivotal trial. Our hope is that the data generated from this study will support the commercialization of Perimeter B-Series, supporting our aim to transform cancer surgery by delivering technology that improves patient outcomes and reduces health care costs."

About Perimeter Medical Imaging AI Inc.

Based in Toronto, Canada, and Dallas, Tex., Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the United States, the company's FDA-cleared (U.S. Food and Drug Administration) Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents the company's next-generation artificial intelligence technology, which is currently being evaluated in a pivotal clinical trial, with support from a grant of up to $7.4-million (U.S.) awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol, PINK, is a reference to the pink ribbons used during Breast Cancer Awareness Month.

We seek Safe Harbor.